Manageable safety profile and promising efficacy in heavily pretreated patients with R/R Non-Hodgin Lymphoma

In this MEDtalk, Jean Marie Michot, MD, Paris, presents insights from poster S216  at EHA22, where a Cereblon E3 Ligase Modulator agent in monotherapy demostrate a showed a manageable safety profile and promising efficacy in heavily pretreated patients with R/R Non-Hodgin Lymphoma.